What is AMR and why is it important for Investors?

< 1 minute read time

ESG in 10 Podcast: Antimicrobial Resistance (AMR), What is it, and why is it important for Investors?

This podcast was originally published on our partner Fidante’s website.

Antimicrobials, especially antibiotics, have been vital in saving lives and improving life expectancy. However, rising antimicrobial resistance poses a significant threat, emphasising the importance of responsible use and research into alternatives.

Moana Nottage joined Fidante’s ‘ESG in 10’ podcast to discuss her research into Antimicrobial Resistance (AMR) and the importance of integrating AMR as a factor into the investment and stewardship process.

Listen now on: Apple, Spotify or Podbean.

Related articles:

In this short 3-minute video, Moana Nottage, and Elfreda Jonker discuss antimicrobial resistance and why it is becoming an emerging ESG consideration.

[button-link link=”https://www.alphinity.com.au/antimicrobial-resistance-relevance-to-investors/”]Read Report[/button-link]

This report explores the ESG considerations related to AMR and the importance of stewardship and company engagement in the healthcare and food sectors to address this risk.

[button-link link=”https://www.alphinity.com.au/is-googles-lamda-chatbot-sentient/“]Watch Now[/button-link]



This material has been prepared by Alphinity Investment Management ABN 12 140 833 709 AFSL 356 895 (Alphinity). It is general information only and is not intended to provide you with financial advice or take into account your objectives, financial situation or needs. To the extent permitted by law, no liability is accepted for any loss or damage as a result of any reliance on this information. Any projections are based on assumptions which we believe are reasonable but are subject to change and should not be relied upon. Past performance is not a reliable indicator of future performance. Neither any particular rate of return nor capital invested are guaranteed.